Pay in 4 interest-free payments of $6.60 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Off-label coverage (not applicable here): An insurer agrees to pay for a medication used off-label
The peptide has also been shown to be equally as potent at stimulating melanogenesis as the related, FDA-approved peptide called afemelanotide (MT-I) [1]
Small molecules are inherently stable in the gut, easily absorbed from the intestine, and do not require special co-formulation
A complete titration from 1mg to 12mg requires 108mg of total retatrutide over 20 weeks
At this time, it is uncertain how participating beneficiaries will be able to maintain Medicare coverage of their GLP-1 medication for obesity after the Medicare GLP-1 Bridge ends at the end of 2027, pending further action from CMS to implement the BALANCE Model in Medicare Part D in 2028, as described below
Ophthalmol Retina, 1 (4), 294-303
